Pharmaceuticals & Therapeutics

EMD Serono and the Trump Administration launch a new program offering massive discounts on IVF drugs, bringing hope to millions of aspiring parents.

Aucta Pharma launches two rare disease drugs, PYQUVI and ZELVYSIA, betting on a 'branded-generic' model to navigate highly competitive markets.

Kelun-Biotech's sac-TMT gains its fourth approval in China, doubling survival time for patients with advanced HR+/HER2- breast cancer.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Akeso's innovative dual-action antibody secures its fifth breakthrough nod, offering a lifeline for patients with advanced biliary tract cancer.

Stunning real-world data shows Iovance's Amtagvi is more effective in earlier melanoma treatment, potentially changing clinical practice and offering new hope.

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

Employers are ditching fragmented vendors for unified platforms that promise to cut costs and complexity, fueling a surge in healthcare technology M&A.

A new drug from Bayer dramatically cuts recurrent stroke risk by 26% without the dangerous bleeding side effects of current therapies, offering hope to millions.

A new study reveals why Sickle Cell Disease patients suffer from frequent crises and rely on pain pills, even with awareness of multi-million dollar cures.

With a massively oversubscribed bond sale and upgraded credit ratings, Italian API giant FIS solidifies its finances to expand in a booming pharma market.

For the third consecutive year, Virginia Cancer Specialists has been named the top practice in Virginia. We explore how they achieved this sustained success.

With backing from top VCs, Angitia Biopharmaceuticals is accelerating its novel treatments for osteoporosis and rare bone disorders. Here's why it matters.

Pluristyx and Solesis launch a 'three-in-one' kit with nearly 100% efficiency in iPSC transfection, tackling a major bottleneck in organoid research.

A new report reveals how GLP-1 drugs are accelerating a major healthcare shift in the Gulf, turning metabolic health into a core economic and policy issue.

The UK-based firm's STIMULAN® is now the only EU-certified calcium matrix for combined antibiotic use, revolutionizing bone infection treatment.

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

With a fresh capital infusion extending its runway into 2027, GRI Bio pushes ahead with promising clinical data for its IPF and autoimmune disease pipeline.

Beyond Cancer is set to reveal early human trial data for its novel nitric oxide therapy, a move that could expand its parent company into oncology.